Putting patients at the heart of care: Sacubitril/valsartan improves physical and social activity impairment in HFrEF
Heart failure (HF) is a global public health concern, affecting about 38 million individuals globally.1 Despite significant medical advances, HF remains a chronic and progressive condition that can negatively affect patients’ quality of life (QoL).2,3 In this case study, Dr Abdul Muizz shares his clinical experience in managing a patient with HF and reduced ejection fraction (HFrEF), following the percutaneous coronary intervention, showing how the initiation of sacubitril/valsartan therapy (an angiotensin receptor/neprilysin inhibitor [ARNI]) changed the clinical outcome of this patient.

New Molecule

3 New

New Formulation

1 New

New Indication

1 New

New Brand

15 New

Color 1
Color 2
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in